(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 15 January 2004 (15.01.2004)

(10) International Publication Number WO 2004/004746 A1

(51) International Patent Classification7: 31/70, C07H 15/203

A61K 35/78,

(21) International Application Number:

PCT/EP2003/007270

(22) International Filing Date:

7 July 2003 (07.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 2002/0428

8 July 2002 (08.07.2002)

(71) Applicant and

(72) Inventor: D'OOSTERLYNCK, André [BE/BE]; Museumlaan 17, B-9830 Sint-Martens-Latem (BE).

(75) Inventor/Applicant (for US only): RAES, Stefaan [BE/BE]; Oude Gaverse Steenweg 82a, B-9820 Merelbeke

BRANTS, Johan, Philippe, Emile; De Clercq, Brants & Partners, E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SIMMONDSIN FOR USE AS AN ANGIOGENESIS INHIBITOR

(57) Abstract: The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, pharmaceutically acceptable esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for treating angiogenesisrelated diseases. The present invention further relates to pharmaceutical compositions for inhibiting angiogenesis or for treating angiogenesis-related diseases in humans or animals and to methods for inhibiting angiogenesis and for treating angiogenesis-related diseases in humans or animals.

